Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant, a small molecule oral ...
On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 ...
BAGSVAERD, Denmark I 19, 2024 I Novo Nordisk today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human ...
The firms will collaborate on two lead programs and up to five future targets in other diseases, with NanoVation eligible for up to $600 million in payments from Novo Nordisk.
Novo Nordisk's shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental ...
Novo Nordisk and NanoVation will collaborate on two lead programs to develop base-editing therapies for certain rare genetic diseases. NanoVation’s lcLNP technology has demonstrated the ability ...
Bagsværd, Denmark Saturday, September 21, 2024, 15:00 Hrs [IST] ...
Novo Nordisk Just Took a $530 Million Step Onto Moderna's Turf. Here's What It Means for Both Stocks
On Sept. 16 Novo Nordisk (NYSE: NVO) and Korro Bio (NASDAQ: KRRO) announced that they'd be starting a new drug-development collaboration worth hundreds of millions of dollars, in an area that most ...
Novo Nordisk fell more than 4% on Friday to their lowest level since Aug. 10 after the Danish drugmaker reported results from ...
Under terms of the deal, Novo Nordisk will get an exclusive license to use NanoVation’s lipid nanoparticle technology for two lead programs, and NanoVation will receive up to US$600 million in ...
Novo Nordisk's weight-loss drugs ... including one in North Carolina, one in Denmark, and one in Brazil. It's also expanding a number of its existing facilities in Denmark. Meanwhile, over ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback